Cidara Therapeutics, Inc. (CDTX) 10-Year Financial Performance & Capital Metrics

CDTX • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

AboutCidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.Show more

Revenue $1M -94.5%
EBITDA -$176M -552.6%
Net Income -$170M -640.6%
EPS (Diluted) -26.75 -409.5%
Gross Margin 100% +272.7%
EBITDA Margin -13793.65% -11817.7%
Operating Margin -13811.92% -11784.1%
Net Margin -13319.76% -13424.2%
ROE -218.99%
ROIC -
Debt/Equity 0.02
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 98 (top 2%)
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Sales declining 42.9% over 5 years
✗Shares diluted 45.3% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-42.85%

3Y-70.48%

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-50.03%

EPS CAGR

10Y-

5Y-

3Y-

TTM53.79%

ROCE

10Y Avg-202.8%

5Y Avg-335.09%

3Y Avg-434.89%

Latest-213.65%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	20.91M	12.07M	49.57M	64.45M	23.28M	1.27M
Revenue Growth %	-	-	-	-	-	-0.42%	3.11%	0.3%	-0.64%	-0.95%
Cost of Goods Sold+	461K	732K	667K	523K	46.4M	0	73.09M	0	36.76M	0
COGS % of Revenue	-	-	-	-	2.22%	-	1.47%	-	1.58%	-
Gross Profit+	-461K	-732K	-667K	-523K	-25.49M	12.07M	-23.52M	64.45M	-13.48M	1.27M
Gross Margin %	-	-	-	-	-1.22%	1%	-0.47%	1%	-0.58%	1%
Gross Profit Growth %	-	-0.59%	0.09%	0.22%	-47.73%	1.47%	-2.95%	3.74%	-1.21%	1.09%
Operating Expenses+	32.31M	48.44M	55.72M	63.28M	62.64M	83.92M	18.74M	97.95M	13.58M	177.38M
OpEx % of Revenue	-	-	-	-	2.99%	6.95%	0.38%	1.52%	0.58%	139.12%
Selling, General & Admin	8.84M	12.74M	12.9M	14.14M	16.24M	15.9M	18.74M	20.55M	13.58M	20.61M
SG&A % of Revenue	-	-	-	-	0.78%	1.32%	0.38%	0.32%	0.58%	16.17%
Research & Development	23.48M	35.7M	42.82M	49.14M	46.4M	68.02M	73.09M	77.41M	36.76M	156.76M
R&D % of Revenue	-	-	-	-	2.22%	5.64%	1.47%	1.2%	1.58%	122.95%
Other Operating Expenses	0	0	0	-211K	0	0	-73.09M	0	-36.76M	0
Operating Income+	-32.31M	-48.44M	-55.72M	-63.28M	-41.72M	-71.85M	-42.26M	-33.5M	-27.06M	-176.1M
Operating Margin %	-	-	-	-	-1.99%	-5.95%	-0.85%	-0.52%	-1.16%	-138.12%
Operating Income Growth %	-1.78%	-0.5%	-0.15%	-0.14%	0.34%	-0.72%	0.41%	0.21%	0.19%	-5.51%
EBITDA+	-31.85M	-47.7M	-55.05M	-62.76M	-41.4M	-70.8M	-42.07M	-33.36M	-26.95M	-175.87M
EBITDA Margin %	-	-	-	-	-1.98%	-5.87%	-0.85%	-0.52%	-1.16%	-137.94%
EBITDA Growth %	-1.78%	-0.5%	-0.15%	-0.14%	0.34%	-0.71%	0.41%	0.21%	0.19%	-5.53%
D&A (Non-Cash Add-back)	461K	732K	667K	523K	328K	1.05M	189K	143K	112K	233K
EBIT	-32.19M	-48.44M	-55.72M	-63.28M	-41.72M	-71.85M	-42.26M	-33.5M	-27.06M	-176.1M
Net Interest Income+	0	0	-7K	0	221K	-262K	0	191K	2M	5.81M
Interest Income	0	0	0	0	221K	0	0	191K	2M	5.81M
Interest Expense	120K	271K	7K	629K	0	262K	0	0	0	0
Other Income/Expense	120K	271K	-7K	4.27M	632K	-262K	-212K	191K	2M	5.81M
Pretax Income+	-32.19M	-48.16M	-55.73M	-59.02M	-41.09M	-72.11M	-42.47M	-33.31M	-25.07M	-170.29M
Pretax Margin %	-	-	-	-	-1.96%	-5.98%	-0.86%	-0.52%	-1.08%	-133.56%
Income Tax+	0	0	0	0	0	0	0	272K	15K	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1.01%	0.91%	1%
Net Income+	-32.19M	-48.16M	-55.73M	-59.02M	-41.09M	-72.11M	-42.47M	-33.58M	-22.93M	-169.83M
Net Margin %	-	-	-	-	-1.96%	-5.98%	-0.86%	-0.52%	-0.98%	-133.2%
Net Income Growth %	-1.71%	-0.5%	-0.16%	-0.06%	0.3%	-0.75%	0.41%	0.21%	0.32%	-6.41%
Net Income (Continuing)	-32.19M	-48.16M	-55.73M	-59.02M	-41.09M	-72.11M	-42.47M	-33.58M	-25.08M	-170.29M
Discontinued Operations	0	0	0	0	0	0	0	0	2.15M	464K
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-46.76	-66.49	-63.69	-45.62	-26.78	-36.03	-16.19	-9.61	-5.25	-26.75
EPS Growth %	0.84%	-0.42%	0.04%	0.28%	0.41%	-0.35%	0.55%	0.41%	0.45%	-4.1%
EPS (Basic)	-46.76	-66.49	-63.69	-45.62	-26.78	-36.03	-16.20	-9.61	-5.25	-26.75
Diluted Shares Outstanding	688.48K	724.45K	875.04K	1.29M	1.5M	2.08M	2.62M	3.49M	4.37M	6.35M
Basic Shares Outstanding	688.48K	724.45K	875.04K	1.29M	1.5M	2.08M	2.62M	3.49M	4.37M	6.35M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	108.22M	105.4M	77.67M	77.13M	65.81M	57.19M	71.7M	45.09M	60.85M	210.74M
Cash & Short-Term Investments	107.51M	104.62M	75.31M	74.56M	50.27M	35.91M	62.27M	32.73M	35.78M	189.82M
Cash Only	107.51M	104.62M	75.31M	74.56M	50.27M	35.91M	62.27M	32.73M	35.78M	189.82M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	321K	0	10K	11.18M	5.36M	5.83M	16.25M	1.69M
Days Sales Outstanding	-	-	-	-	0.17	338.02	39.44	33.04	254.68	484.95
Inventory	0	0	-321K	0	0	0	-2.59M	0	6.1M	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	60.53	-
Other Current Assets	704K	779K	0	2.57M	10M	7.04M	2.59M	0	2.73M	19.22M
Total Non-Current Assets+	1.76M	1.56M	1.36M	1.98M	3.16M	3.23M	3.63M	2.39M	6.17M	4.06M
Property, Plant & Equipment	1.68M	1.37M	1.04M	712K	2.06M	1.21M	2.54M	1.32M	5.13M	3.96M
Fixed Asset Turnover	-	-	-	-	10.15x	9.97x	19.49x	48.79x	4.54x	0.32x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	72K	190K	321K	1.27M	1.1M	2.02M	533K	1.07M	1.05M	96K
Total Assets+	109.97M	106.96M	79.03M	79.11M	68.98M	60.42M	75.33M	47.49M	67.03M	214.8M
Asset Turnover	-	-	-	-	0.30x	0.20x	0.66x	1.36x	0.35x	0.01x
Asset Growth %	3.52%	-0.03%	-0.26%	0%	-0.13%	-0.12%	0.25%	-0.37%	0.41%	2.2%
Total Current Liabilities+	5.97M	8.91M	12.09M	19.89M	30.2M	38.56M	34.02M	41.4M	67.42M	49.55M
Accounts Payable	3.1M	2.91M	2.59M	2.85M	1.89M	4.57M	1.3M	1.45M	3.77M	3.61M
Days Payables Outstanding	2.45K	1.45K	1.42K	1.99K	14.84	-	6.5	-	37.45	-
Short-Term Debt	0	0	2.67M	9.93M	9.96M	7.02M	2.59M	0	0	0
Deferred Revenue (Current)	0	0	0	1000K	1000K	1000K	1000K	1000K	1000K	0
Other Current Liabilities	0	0	0	4.29M	3.66M	4.21M	10.2M	4.92M	32.22M	44.3M
Current Ratio	18.11x	11.83x	6.43x	3.88x	2.18x	1.48x	2.11x	1.09x	0.90x	4.25x
Quick Ratio	18.11x	11.83x	6.45x	3.88x	2.18x	1.48x	2.18x	1.09x	0.81x	4.25x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	277.77	-
Total Non-Current Liabilities+	6.06M	9.87M	7.21M	81K	942K	11.14M	19.73M	20.52M	7.82M	1.93M
Long-Term Debt	0	9.79M	7.21M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	942K	0	1.32M	0	3.58M	1.93M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	88K	80K	0	81K	0	0	0	0	0	0
Total Liabilities	6.06M	18.78M	19.29M	19.97M	31.14M	49.71M	53.75M	61.92M	75.24M	51.49M
Total Debt+	0	9.79M	9.87M	9.93M	11.72M	7.96M	5.06M	1.21M	4.88M	3.58M
Net Debt	-107.51M	-94.83M	-65.44M	-64.63M	-38.54M	-27.95M	-57.21M	-31.52M	-30.9M	-186.25M
Debt / Equity	-	0.11x	0.17x	0.17x	0.31x	0.74x	0.23x	-	-	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-269.28x	-178.73x	-7960.14x	-100.61x	-	-274.23x	-	-	-	-
Total Equity+	103.91M	88.18M	59.74M	59.14M	37.84M	10.71M	21.57M	-14.44M	-8.21M	163.31M
Equity Growth %	3.92%	-0.15%	-0.32%	-0.01%	-0.36%	-0.72%	1.01%	-1.67%	0.43%	20.89%
Book Value per Share	150.93	121.72	68.28	45.72	25.28	5.16	8.23	-4.13	-1.88	25.72
Total Shareholders' Equity	103.91M	88.18M	59.74M	59.14M	37.84M	10.71M	21.57M	-14.44M	-8.21M	163.31M
Common Stock	1K	2K	2K	3K	3K	4K	7K	7K	9K	1K
Retained Earnings	-45.5M	-93.66M	-149.39M	-218.74M	-259.83M	-334.7M	-377.17M	-418.5M	-441.43M	-611.26M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-8K	-1K	-8K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-25.96M	-39.77M	-49.91M	-56.7M	-28.53M	-54.41M	-25.23M	-28.47M	-22.43M	-176.53M
Operating CF Margin %	-	-	-	-	-1.36%	-4.51%	-0.51%	-0.44%	-0.96%	-138.46%
Operating CF Growth %	-2.37%	-0.53%	-0.25%	-0.14%	0.5%	-0.91%	0.54%	-0.13%	0.21%	-6.87%
Net Income	-32.19M	-48.16M	-55.73M	-59.02M	-41.09M	-72.11M	-42.47M	-33.58M	-22.93M	-169.83M
Depreciation & Amortization	461K	732K	667K	523K	375K	229K	-1.23M	143K	118K	233K
Stock-Based Compensation	3.03M	4.34M	5.71M	5.71M	5.07M	4.09M	4.01M	3.53M	3.06M	3.91M
Deferred Taxes	-42K	-176K	-33K	-3.61M	-411K	0	0	0	0	0
Other Non-Cash Items	76K	14K	50K	86K	36K	21K	15K	982K	1.24M	3.09M
Working Capital Changes	2.71M	3.48M	-579K	-399K	7.49M	13.36M	14.44M	454K	-3.92M	-13.93M
Change in Receivables	0	0	0	321K	-10K	-11.16M	5.82M	-477K	-10.41M	14.28M
Change in Inventory	0	0	0	0	10K	-6.59M	1.09M	0	-6.1M	6.1M
Change in Payables	2.14M	1.91M	642K	-59K	-784K	6.59M	-1.09M	-2.37M	8.89M	-1M
Cash from Investing+	-46.09M	25.48M	4.47M	14.3M	-35K	-186K	-41K	-118K	-505K	-129K
Capital Expenditures	-1.17M	-401K	-306K	-177K	-35K	-186K	-41K	-118K	-505K	-129K
CapEx % of Revenue	-	-	-	-	0%	0.02%	0%	0%	0.02%	0.1%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-44.92M	25.88M	4.78M	14.48M	0	0	0	0	0	0
Cash from Financing+	111.81M	37.09M	20.88M	56.15M	14.27M	37.28M	44.6M	-951K	25.98M	337.06M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	387K	525K	228K	49.71M	-24K	14K	6K	-720K	21K	7K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-27.13M	-40.17M	-50.22M	-56.88M	-28.57M	-54.6M	-25.27M	-28.59M	-22.94M	-176.66M
FCF Margin %	-	-	-	-	-1.37%	-4.52%	-0.51%	-0.44%	-0.99%	-138.56%
FCF Growth %	-2.12%	-0.48%	-0.25%	-0.13%	0.5%	-0.91%	0.54%	-0.13%	0.2%	-6.7%
FCF per Share	-39.40	-55.45	-57.39	-43.97	-19.09	-26.28	-9.64	-8.19	-5.25	-27.82
FCF Conversion (FCF/Net Income)	0.81x	0.83x	0.90x	0.96x	0.69x	0.75x	0.59x	0.85x	0.98x	1.04x
Interest Paid	0	0	0	0	0	0	0	40K	0	0
Taxes Paid	0	0	0	0	0	0	0	0	797K	95K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-51.5%	-50.15%	-75.35%	-99.28%	-84.75%	-297.06%	-263.05%	-941.39%	-	-218.99%
Gross Margin	-	-	-	-	-121.86%	100%	-47.44%	100%	-57.9%	100%
Net Margin	-	-	-	-	-196.47%	-597.59%	-85.67%	-52.11%	-98.49%	-13319.76%
Debt / Equity	-	0.11x	0.17x	0.17x	0.31x	0.74x	0.23x	-	-	0.02x
Interest Coverage	-269.28x	-178.73x	-7960.14x	-100.61x	-	-274.23x	-	-	-	-
FCF Conversion	0.81x	0.83x	0.90x	0.96x	0.69x	0.75x	0.59x	0.85x	0.98x	1.04x
Revenue Growth	-	-	-	-	-	-42.3%	310.81%	30.01%	-63.87%	-94.52%

Revenue by Segment

	2024
Reportable	1.27M
Reportable Growth	-

Frequently Asked Questions

Growth & Financials

Cidara Therapeutics, Inc. (CDTX) reported $1.3M in revenue for fiscal year 2024.

Cidara Therapeutics, Inc. (CDTX) saw revenue decline by 94.5% over the past year.

Cidara Therapeutics, Inc. (CDTX) reported a net loss of $184.7M for fiscal year 2024.

Dividend & Returns

Cidara Therapeutics, Inc. (CDTX) has a return on equity (ROE) of -219.0%. Negative ROE indicates the company is unprofitable.

Cidara Therapeutics, Inc. (CDTX) had negative free cash flow of $132.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Cidara Therapeutics, Inc. (CDTX) 10-Year Financial Performance & Capital Metrics

CDTX • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

Revenue $1M -94.5%
EBITDA -$176M -552.6%
Net Income -$170M -640.6%
EPS (Diluted) -26.75 -409.5%
Gross Margin 100% +272.7%
EBITDA Margin -13793.65% -11817.7%
Operating Margin -13811.92% -11784.1%
Net Margin -13319.76% -13424.2%
ROE -218.99%
ROIC -
Debt/Equity 0.02
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 98 (top 2%)
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Sales declining 42.9% over 5 years
✗Shares diluted 45.3% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-42.85%

3Y-70.48%

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-50.03%

EPS CAGR

10Y-

5Y-

3Y-

TTM53.79%

ROCE

10Y Avg-202.8%

5Y Avg-335.09%

3Y Avg-434.89%

Latest-213.65%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	20.91M	12.07M	49.57M	64.45M	23.28M	1.27M
Revenue Growth %	-	-	-	-	-	-0.42%	3.11%	0.3%	-0.64%	-0.95%
Cost of Goods Sold+	461K	732K	667K	523K	46.4M	0	73.09M	0	36.76M	0
COGS % of Revenue	-	-	-	-	2.22%	-	1.47%	-	1.58%	-
Gross Profit+	-461K	-732K	-667K	-523K	-25.49M	12.07M	-23.52M	64.45M	-13.48M	1.27M
Gross Margin %	-	-	-	-	-1.22%	1%	-0.47%	1%	-0.58%	1%
Gross Profit Growth %	-	-0.59%	0.09%	0.22%	-47.73%	1.47%	-2.95%	3.74%	-1.21%	1.09%
Operating Expenses+	32.31M	48.44M	55.72M	63.28M	62.64M	83.92M	18.74M	97.95M	13.58M	177.38M
OpEx % of Revenue	-	-	-	-	2.99%	6.95%	0.38%	1.52%	0.58%	139.12%
Selling, General & Admin	8.84M	12.74M	12.9M	14.14M	16.24M	15.9M	18.74M	20.55M	13.58M	20.61M
SG&A % of Revenue	-	-	-	-	0.78%	1.32%	0.38%	0.32%	0.58%	16.17%
Research & Development	23.48M	35.7M	42.82M	49.14M	46.4M	68.02M	73.09M	77.41M	36.76M	156.76M
R&D % of Revenue	-	-	-	-	2.22%	5.64%	1.47%	1.2%	1.58%	122.95%
Other Operating Expenses	0	0	0	-211K	0	0	-73.09M	0	-36.76M	0
Operating Income+	-32.31M	-48.44M	-55.72M	-63.28M	-41.72M	-71.85M	-42.26M	-33.5M	-27.06M	-176.1M
Operating Margin %	-	-	-	-	-1.99%	-5.95%	-0.85%	-0.52%	-1.16%	-138.12%
Operating Income Growth %	-1.78%	-0.5%	-0.15%	-0.14%	0.34%	-0.72%	0.41%	0.21%	0.19%	-5.51%
EBITDA+	-31.85M	-47.7M	-55.05M	-62.76M	-41.4M	-70.8M	-42.07M	-33.36M	-26.95M	-175.87M
EBITDA Margin %	-	-	-	-	-1.98%	-5.87%	-0.85%	-0.52%	-1.16%	-137.94%
EBITDA Growth %	-1.78%	-0.5%	-0.15%	-0.14%	0.34%	-0.71%	0.41%	0.21%	0.19%	-5.53%
D&A (Non-Cash Add-back)	461K	732K	667K	523K	328K	1.05M	189K	143K	112K	233K
EBIT	-32.19M	-48.44M	-55.72M	-63.28M	-41.72M	-71.85M	-42.26M	-33.5M	-27.06M	-176.1M
Net Interest Income+	0	0	-7K	0	221K	-262K	0	191K	2M	5.81M
Interest Income	0	0	0	0	221K	0	0	191K	2M	5.81M
Interest Expense	120K	271K	7K	629K	0	262K	0	0	0	0
Other Income/Expense	120K	271K	-7K	4.27M	632K	-262K	-212K	191K	2M	5.81M
Pretax Income+	-32.19M	-48.16M	-55.73M	-59.02M	-41.09M	-72.11M	-42.47M	-33.31M	-25.07M	-170.29M
Pretax Margin %	-	-	-	-	-1.96%	-5.98%	-0.86%	-0.52%	-1.08%	-133.56%
Income Tax+	0	0	0	0	0	0	0	272K	15K	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1.01%	0.91%	1%
Net Income+	-32.19M	-48.16M	-55.73M	-59.02M	-41.09M	-72.11M	-42.47M	-33.58M	-22.93M	-169.83M
Net Margin %	-	-	-	-	-1.96%	-5.98%	-0.86%	-0.52%	-0.98%	-133.2%
Net Income Growth %	-1.71%	-0.5%	-0.16%	-0.06%	0.3%	-0.75%	0.41%	0.21%	0.32%	-6.41%
Net Income (Continuing)	-32.19M	-48.16M	-55.73M	-59.02M	-41.09M	-72.11M	-42.47M	-33.58M	-25.08M	-170.29M
Discontinued Operations	0	0	0	0	0	0	0	0	2.15M	464K
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-46.76	-66.49	-63.69	-45.62	-26.78	-36.03	-16.19	-9.61	-5.25	-26.75
EPS Growth %	0.84%	-0.42%	0.04%	0.28%	0.41%	-0.35%	0.55%	0.41%	0.45%	-4.1%
EPS (Basic)	-46.76	-66.49	-63.69	-45.62	-26.78	-36.03	-16.20	-9.61	-5.25	-26.75
Diluted Shares Outstanding	688.48K	724.45K	875.04K	1.29M	1.5M	2.08M	2.62M	3.49M	4.37M	6.35M
Basic Shares Outstanding	688.48K	724.45K	875.04K	1.29M	1.5M	2.08M	2.62M	3.49M	4.37M	6.35M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	108.22M	105.4M	77.67M	77.13M	65.81M	57.19M	71.7M	45.09M	60.85M	210.74M
Cash & Short-Term Investments	107.51M	104.62M	75.31M	74.56M	50.27M	35.91M	62.27M	32.73M	35.78M	189.82M
Cash Only	107.51M	104.62M	75.31M	74.56M	50.27M	35.91M	62.27M	32.73M	35.78M	189.82M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	321K	0	10K	11.18M	5.36M	5.83M	16.25M	1.69M
Days Sales Outstanding	-	-	-	-	0.17	338.02	39.44	33.04	254.68	484.95
Inventory	0	0	-321K	0	0	0	-2.59M	0	6.1M	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	60.53	-
Other Current Assets	704K	779K	0	2.57M	10M	7.04M	2.59M	0	2.73M	19.22M
Total Non-Current Assets+	1.76M	1.56M	1.36M	1.98M	3.16M	3.23M	3.63M	2.39M	6.17M	4.06M
Property, Plant & Equipment	1.68M	1.37M	1.04M	712K	2.06M	1.21M	2.54M	1.32M	5.13M	3.96M
Fixed Asset Turnover	-	-	-	-	10.15x	9.97x	19.49x	48.79x	4.54x	0.32x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	72K	190K	321K	1.27M	1.1M	2.02M	533K	1.07M	1.05M	96K
Total Assets+	109.97M	106.96M	79.03M	79.11M	68.98M	60.42M	75.33M	47.49M	67.03M	214.8M
Asset Turnover	-	-	-	-	0.30x	0.20x	0.66x	1.36x	0.35x	0.01x
Asset Growth %	3.52%	-0.03%	-0.26%	0%	-0.13%	-0.12%	0.25%	-0.37%	0.41%	2.2%
Total Current Liabilities+	5.97M	8.91M	12.09M	19.89M	30.2M	38.56M	34.02M	41.4M	67.42M	49.55M
Accounts Payable	3.1M	2.91M	2.59M	2.85M	1.89M	4.57M	1.3M	1.45M	3.77M	3.61M
Days Payables Outstanding	2.45K	1.45K	1.42K	1.99K	14.84	-	6.5	-	37.45	-
Short-Term Debt	0	0	2.67M	9.93M	9.96M	7.02M	2.59M	0	0	0
Deferred Revenue (Current)	0	0	0	1000K	1000K	1000K	1000K	1000K	1000K	0
Other Current Liabilities	0	0	0	4.29M	3.66M	4.21M	10.2M	4.92M	32.22M	44.3M
Current Ratio	18.11x	11.83x	6.43x	3.88x	2.18x	1.48x	2.11x	1.09x	0.90x	4.25x
Quick Ratio	18.11x	11.83x	6.45x	3.88x	2.18x	1.48x	2.18x	1.09x	0.81x	4.25x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	277.77	-
Total Non-Current Liabilities+	6.06M	9.87M	7.21M	81K	942K	11.14M	19.73M	20.52M	7.82M	1.93M
Long-Term Debt	0	9.79M	7.21M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	942K	0	1.32M	0	3.58M	1.93M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	88K	80K	0	81K	0	0	0	0	0	0
Total Liabilities	6.06M	18.78M	19.29M	19.97M	31.14M	49.71M	53.75M	61.92M	75.24M	51.49M
Total Debt+	0	9.79M	9.87M	9.93M	11.72M	7.96M	5.06M	1.21M	4.88M	3.58M
Net Debt	-107.51M	-94.83M	-65.44M	-64.63M	-38.54M	-27.95M	-57.21M	-31.52M	-30.9M	-186.25M
Debt / Equity	-	0.11x	0.17x	0.17x	0.31x	0.74x	0.23x	-	-	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-269.28x	-178.73x	-7960.14x	-100.61x	-	-274.23x	-	-	-	-
Total Equity+	103.91M	88.18M	59.74M	59.14M	37.84M	10.71M	21.57M	-14.44M	-8.21M	163.31M
Equity Growth %	3.92%	-0.15%	-0.32%	-0.01%	-0.36%	-0.72%	1.01%	-1.67%	0.43%	20.89%
Book Value per Share	150.93	121.72	68.28	45.72	25.28	5.16	8.23	-4.13	-1.88	25.72
Total Shareholders' Equity	103.91M	88.18M	59.74M	59.14M	37.84M	10.71M	21.57M	-14.44M	-8.21M	163.31M
Common Stock	1K	2K	2K	3K	3K	4K	7K	7K	9K	1K
Retained Earnings	-45.5M	-93.66M	-149.39M	-218.74M	-259.83M	-334.7M	-377.17M	-418.5M	-441.43M	-611.26M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-8K	-1K	-8K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-25.96M	-39.77M	-49.91M	-56.7M	-28.53M	-54.41M	-25.23M	-28.47M	-22.43M	-176.53M
Operating CF Margin %	-	-	-	-	-1.36%	-4.51%	-0.51%	-0.44%	-0.96%	-138.46%
Operating CF Growth %	-2.37%	-0.53%	-0.25%	-0.14%	0.5%	-0.91%	0.54%	-0.13%	0.21%	-6.87%
Net Income	-32.19M	-48.16M	-55.73M	-59.02M	-41.09M	-72.11M	-42.47M	-33.58M	-22.93M	-169.83M
Depreciation & Amortization	461K	732K	667K	523K	375K	229K	-1.23M	143K	118K	233K
Stock-Based Compensation	3.03M	4.34M	5.71M	5.71M	5.07M	4.09M	4.01M	3.53M	3.06M	3.91M
Deferred Taxes	-42K	-176K	-33K	-3.61M	-411K	0	0	0	0	0
Other Non-Cash Items	76K	14K	50K	86K	36K	21K	15K	982K	1.24M	3.09M
Working Capital Changes	2.71M	3.48M	-579K	-399K	7.49M	13.36M	14.44M	454K	-3.92M	-13.93M
Change in Receivables	0	0	0	321K	-10K	-11.16M	5.82M	-477K	-10.41M	14.28M
Change in Inventory	0	0	0	0	10K	-6.59M	1.09M	0	-6.1M	6.1M
Change in Payables	2.14M	1.91M	642K	-59K	-784K	6.59M	-1.09M	-2.37M	8.89M	-1M
Cash from Investing+	-46.09M	25.48M	4.47M	14.3M	-35K	-186K	-41K	-118K	-505K	-129K
Capital Expenditures	-1.17M	-401K	-306K	-177K	-35K	-186K	-41K	-118K	-505K	-129K
CapEx % of Revenue	-	-	-	-	0%	0.02%	0%	0%	0.02%	0.1%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-44.92M	25.88M	4.78M	14.48M	0	0	0	0	0	0
Cash from Financing+	111.81M	37.09M	20.88M	56.15M	14.27M	37.28M	44.6M	-951K	25.98M	337.06M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	387K	525K	228K	49.71M	-24K	14K	6K	-720K	21K	7K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-27.13M	-40.17M	-50.22M	-56.88M	-28.57M	-54.6M	-25.27M	-28.59M	-22.94M	-176.66M
FCF Margin %	-	-	-	-	-1.37%	-4.52%	-0.51%	-0.44%	-0.99%	-138.56%
FCF Growth %	-2.12%	-0.48%	-0.25%	-0.13%	0.5%	-0.91%	0.54%	-0.13%	0.2%	-6.7%
FCF per Share	-39.40	-55.45	-57.39	-43.97	-19.09	-26.28	-9.64	-8.19	-5.25	-27.82
FCF Conversion (FCF/Net Income)	0.81x	0.83x	0.90x	0.96x	0.69x	0.75x	0.59x	0.85x	0.98x	1.04x
Interest Paid	0	0	0	0	0	0	0	40K	0	0
Taxes Paid	0	0	0	0	0	0	0	0	797K	95K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-51.5%	-50.15%	-75.35%	-99.28%	-84.75%	-297.06%	-263.05%	-941.39%	-	-218.99%
Gross Margin	-	-	-	-	-121.86%	100%	-47.44%	100%	-57.9%	100%
Net Margin	-	-	-	-	-196.47%	-597.59%	-85.67%	-52.11%	-98.49%	-13319.76%
Debt / Equity	-	0.11x	0.17x	0.17x	0.31x	0.74x	0.23x	-	-	0.02x
Interest Coverage	-269.28x	-178.73x	-7960.14x	-100.61x	-	-274.23x	-	-	-	-
FCF Conversion	0.81x	0.83x	0.90x	0.96x	0.69x	0.75x	0.59x	0.85x	0.98x	1.04x
Revenue Growth	-	-	-	-	-	-42.3%	310.81%	30.01%	-63.87%	-94.52%

Revenue by Segment

	2024
Reportable	1.27M
Reportable Growth	-

Frequently Asked Questions

Growth & Financials

Cidara Therapeutics, Inc. (CDTX) reported $1.3M in revenue for fiscal year 2024.

Cidara Therapeutics, Inc. (CDTX) saw revenue decline by 94.5% over the past year.

Cidara Therapeutics, Inc. (CDTX) reported a net loss of $184.7M for fiscal year 2024.

Dividend & Returns

Cidara Therapeutics, Inc. (CDTX) has a return on equity (ROE) of -219.0%. Negative ROE indicates the company is unprofitable.

Cidara Therapeutics, Inc. (CDTX) had negative free cash flow of $132.9M in fiscal year 2024, likely due to heavy capital investments.